Patents by Inventor John Collinge
John Collinge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10919971Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.Type: GrantFiled: April 30, 2019Date of Patent: February 16, 2021Assignee: D-GEN LIMITEDInventors: John Collinge, Andrew J. Nicoll
-
Publication number: 20190382499Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.Type: ApplicationFiled: April 30, 2019Publication date: December 19, 2019Inventors: John Collinge, Andrew J. Nicoll
-
Patent number: 10316099Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.Type: GrantFiled: July 8, 2016Date of Patent: June 11, 2019Assignee: D-GEN LIMITEDInventors: John Collinge, Andrew J Nicoll
-
Patent number: 10288627Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.Type: GrantFiled: September 13, 2011Date of Patent: May 14, 2019Assignee: D-Gen LimitedInventors: Graham Stuart Jackson, John Collinge, Julie Ann Edgeworth
-
Publication number: 20170066833Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.Type: ApplicationFiled: July 8, 2016Publication date: March 9, 2017Inventors: John COLLINGE, Andrew J. Nicoll
-
Publication number: 20160320413Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.Type: ApplicationFiled: July 19, 2016Publication date: November 3, 2016Inventors: Graham Stuart Jackson, John Collinge, Julie Ann Edgeworth
-
Patent number: 9028801Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No.Type: GrantFiled: December 7, 2005Date of Patent: May 12, 2015Assignees: Electrophoretics Limited, Medical Research Council, University College LondonInventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
-
Publication number: 20140294844Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.Type: ApplicationFiled: May 9, 2012Publication date: October 2, 2014Inventors: John Collinge, Andrew J. Nicoll
-
Publication number: 20130196356Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.Type: ApplicationFiled: September 13, 2011Publication date: August 1, 2013Applicant: D-GEN LIMITEDInventors: Graham Stuart Jackson, John Collinge, Julie Ann Edgeworth
-
Patent number: 8431526Abstract: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.Type: GrantFiled: August 30, 2011Date of Patent: April 30, 2013Assignee: E. I. du Pont de Nemours and CompanyInventors: Vincent Brian Croud, Graham Jackson, John Collinge
-
Publication number: 20110311510Abstract: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.Type: ApplicationFiled: August 30, 2011Publication date: December 22, 2011Inventors: Vincent Brian CROUD, John Collinge, Graham Jackson
-
Patent number: 8034766Abstract: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.Type: GrantFiled: October 26, 2007Date of Patent: October 11, 2011Assignees: E I du Pont de Nemours and Company, University College LondonInventors: Vincent Brian Croud, John Collinge, Graham Jackson
-
Patent number: 7875259Abstract: The present invention relates to a method of making a ?-form of a prion protein which preferably has more ?-sheet than ?-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the ?-form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native ?-form of a prion protein to a ?-form, and to uses of identified compounds in medicine.Type: GrantFiled: May 27, 2005Date of Patent: January 25, 2011Assignee: D-Gen LimitedInventors: John Collinge, Anthony R. Clarke, Graham S. Jackson
-
Patent number: 7550144Abstract: The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.Type: GrantFiled: November 28, 2003Date of Patent: June 23, 2009Assignee: D-Gen LimitedInventors: John Collinge, Simon Hawke
-
Publication number: 20080241861Abstract: The present invention relates to a method of making a ?-form of a prion protein which preferably has more ?-sheet than ?-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the ?-form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native ?-form of a prion protein to a ?-form, and to uses of identified compounds in medicine.Type: ApplicationFiled: October 16, 2007Publication date: October 2, 2008Applicant: D-Gen LimitedInventors: John Collinge, Anthony R. Clarke, Graham S. Jackson
-
Publication number: 20080213802Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No.Type: ApplicationFiled: December 7, 2005Publication date: September 4, 2008Inventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
-
Publication number: 20080206843Abstract: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.Type: ApplicationFiled: October 26, 2007Publication date: August 28, 2008Inventors: Vincent Brian Croud, John Collinge, Graham Jackson
-
Publication number: 20080108085Abstract: The invention relates to methods for determining the presence of prions in a tissue/organ or fluid therefrom; said method comprising the steps of: contacting the tissue/organ with one or more devices, wherein said devices are capable of binding prions; removing said devices from contact with said tissue/organ; determining if said devices are binding prions wherein the device is contacted with the tissue/organ for 120 minutes.Type: ApplicationFiled: April 6, 2007Publication date: May 8, 2008Applicant: D-GEN LIMITEDInventors: Masato Enari, Eckhard Flechsig, John Collinge, Charles Weissmann
-
Publication number: 20060280745Abstract: The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.Type: ApplicationFiled: November 28, 2003Publication date: December 14, 2006Applicant: Medical Research CouncilInventors: John Collinge, Simon Hawke
-
Publication number: 20060217282Abstract: The present invention relates to methods for prion decontamination comprising (i) contacting an entity to be decontaminated with a detergent, (ii) contacting said entity with one or more protease(s), and optionally (iii) autoclaving said entity. The invention further relates to kits comprising detergents and proteases for prion decontamination, and compositions comprising detergents and proteases for prion decontamination.Type: ApplicationFiled: October 29, 2003Publication date: September 28, 2006Inventors: Graham Jackson, John Collinge, Anthony Clarke